BeiGene, Ltd. (ONC)
NASDAQ: ONC · Real-Time Price · USD
177.88
+2.78 (1.59%)
Jan 8, 2025, 4:00 PM EST - Market closed
BeiGene Revenue
BeiGene had revenue of 7.35B CNY in the quarter ending September 30, 2024, with 39.54% growth. This brings the company's revenue in the last twelve months to 23.51B, up 50.22% year-over-year. In the year 2023, BeiGene had annual revenue of 2.46B with 73.65% growth.
Revenue (ttm)
23.51B CNY
Revenue Growth
+50.22%
P/S Ratio
5.54
Revenue / Employee
2,217,710 CNY
Employees
10,600
Market Cap
18.94B USD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2.46B | 1.04B | 73.65% |
Dec 31, 2022 | 1.42B | 239.64M | 20.37% |
Dec 31, 2021 | 1.18B | 867.41M | 280.83% |
Dec 31, 2020 | 308.87M | -119.34M | -27.87% |
Dec 31, 2019 | 428.21M | 229.99M | 116.03% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Amazon.com | 620.13B |
Apple | 391.04B |
Berkshire Hathaway | 369.89B |
Berkshire Hathaway | 369.89B |
Alphabet | 339.86B |
Alphabet | 339.86B |
Microsoft | 254.19B |
Meta Platforms | 156.23B |
ONC News
- 3 days ago - BeiGene Announces Appointment of Giancarlo Benelli as Head of Europe - Business Wire
- 13 days ago - TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy - Business Wire
- 17 days ago - BeiGene to Change Nasdaq Ticker Symbol to “ONC” on January 2; Present at 43rd Annual J.P. Morgan Healthcare Conference - Business Wire
- 27 days ago - BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor - Business Wire
- 4 weeks ago - BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets - Business Wire
- 5 weeks ago - BeiGene and CLL Society Partner to Advance Test Before Treat™ Campaign, Promoting Biomarker Testing to Improve Patient Outcomes in CLL - Business Wire
- 5 weeks ago - BeiGene to Host Investor Webcast Highlighting Key Data from ASH and the San Antonio Breast Cancer Symposium on December 16, 2024 - Business Wire
- 5 weeks ago - BeiGene: Nearing Profitability On TEVIMBRA Approval In The EU And US - Seeking Alpha